DR-091 Organotropism: gaining new insights into the molecular landscape of prostate cancer metastases
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-091 Organotropism: gaining new insights into the molecular landscape of prostate cancer metastases
While localized prostate cancer can be cured, metastastatic disease is associated with high morbidity and mortality. Prostate cancer typically metastasizes …
DR-089 Tumor genotype and the risk of cancer-associatied venous thromboembolsim: results from 4000 cancer biopsies (PANDORA study)
“Venous thromboembolism (VTE), a venous blood clot, frequently occurs in cancer patients, and substantially affects morbidity, quality of life, and …
DR-088 The genomic landscape of renal cell cancer patients
The introduction of new therapeutic options, i.e. antiangiogenic drugs and immunotherapy, has significantly changed the treatment and perspectives of patients …
DR-087 Pan-cancer investigation of intratumor heterogeneity in primary and metastatic disease
We aim to stratify cancer types by the degree of intratumour heterogeneity demonstrated both between metastases (when the cancer spreads) …
DR-086 Optimalisation of chemotherapy response in metastatic colorectal cancer patients based on a patient-specific cellular composition score.
The treatment of metastatic colorectal cancer (mCRC) is still based on traditional chemotherapies. mCRC is a very heterogeneous disease, and …
DR-085 Germline genetic variants underlying the genomic, transcriptomic and clinical characteristics of metastatic breast cancer
Breast cancer is the most common cancer among women Worldwide. Inherited variants in breast cancer susceptibility genes or other regions …
DR-084 Defining bacteria-induced mutational signatures in human tumors
Numerous environmental triggers have been found to leave a footprint on the DNA of human cancers. By treating human cells …
DR-083 Technology Assessment of Next Generation Sequencing in Personalized Oncology (TANGO)
“Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Since 2005, standard treatment consists of …
DR-082 Identification of gene signatures predictive for response to taxane-based treatment regimens
While localized prostate cancer can be cured, metastastatic disease is associated with high morbidity and mortality. Prostate cancer typically metastasizes …
DR-081 Gallbladder cancer, time for improvement: molecular characterization of a rare tumor to identify novel therapeutic targets.
This project concerns a feasibility study, in which tumor biopsies collected in different hospitals in the CPCT-02 trial will be …
DR-080 The tumor-stroma ratio (TSR) as predictor of response to checkpoint inhibitors in patients with gastrointestinal malignancies
“Venous thromboembolism (VTE), a venous blood clot, frequently occurs in cancer patients, and substantially affects morbidity, quality of life, …
DR-079 Technology Assessment of Next Generation Sequencing in Personalized Oncology (TANGO)
The introduction of new therapeutic options, i.e. antiangiogenic drugs and immunotherapy, has significantly changed the treatment and perspectives of patients …
Als je WGS één keer doet bij een patiënt met gemetastaseerde kanker, weet je meteen alles wat je nodig hebt om een gerichte behandeling te bieden als die – geregistreerd of in onderzoeksetting – beschikbaar is.